Deuruxolitinib
Brand names: Leqselvi · Active ingredient: Deuruxolitinib Phosphate
In short: LEQSELVI® is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.
What is Deuruxolitinib used for?
LEQSELVI® is indicated for the treatment of adult patients with severe alopecia areata.
Limitations of Use
LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.
⚠ Boxed warning (FDA's strongest warning)
Increased risk of serious bacterial, fungal, viral and opportunistic infections, including tuberculosis (TB), that may lead to hospitalization or death. Interrupt treatment with LEQSELVI if a serious infection occurs until the infection is controlled. LEQSELVI treatment is not recommended in patients with active tuberculosis. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. (5.1)
Higher rate of all-cause mortality, including sudden cardiovascular death, was observed with another Janus kinase (JAK) inhibitor vs. TNF blockers in rheumatoid arthritis (RA) patients. LEQSELVI is not approved for use in RA patients. (5.2)
Malignancies were reported in patients treated with LEQSELVI. Higher rate of lymphomas and lung cancers was observed with another JAK inhibitor vs. TNF blockers in RA patients. (5.3)
Higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) was observed with another JAK inhibitor vs. TNF blockers in RA patients. (5.4)
Thrombosis, including cerebral venous sinus thrombosis (CVT), deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients treated with LEQSELVI. Increased incidence of pulmonary embolism, venous and arterial thrombosis was observed with another JAK inhibitor vs. TNF blockers. (5.5)
Deuruxolitinib dosage
Perform the following prior to treatment with LEQSELVI:
CYP2C9 genotype determination: Test patients for CYP2C9 variants to determine CYP2C9 genotype. LEQSELVI is contraindicated in patients who are CYP2C9 poor metabolizers (patients with decreased cytochrome P450 (CYP) 2C9 function) . An FDA-cleared or -approved test for the detection of CYP2C9 variants to direct the use of LEQSELVI is not currently available.
Evaluation for use of concomitant CYP2C9 inhibitors: LEQSELVI is contraindicated in patients taking moderate or strong CYP2C9 inhibitors .
Active and latent tuberculosis (TB) evaluation: LEQSELVI treatment is not recommended in patients with active TB. For patients with latent TB or those with a negative latent TB test who are at high risk of TB, start preventive therapy for TB prior to LEQSELVI treatment .
Viral hepatitis screening in accordance with clinical guidelines: LEQSELVI treatment is not recommended in patients with active hepatitis B or hepatitis C.
Hepatitis B infection screening: If hepatitis B infection is discovered, follow hepatitis B clinical guidelines, or refer to a liver specialist. Monitor patients for reactivation in accordance with clinical guidelines during treatment .
Complete blood count (CBC): LEQSELVI treatment is not recommended in patients with an absolute lymphocyte count (ALC) <500 cells/mm3 absolute neutrophil count (ANC) <1,000 cells/mm3, or hemoglobin level <8 g/dl. Monitor complete blood counts periodically during treatment and modify dosage as recommended .
Complete any necessary immunizations, including herpes zoster vaccinations, according to current immunization guidelines prior to LEQSELVI treatment .
The recommended dosage of LEQSELVI for the treatment of severe alopecia areata is 8 mg orally twice daily, with or without food .
If a dose is missed, skip the missed dose and resume dosing at the next scheduled dose.
Serious or Opportunistic Infections
If a patient develops a serious or opportunistic infection, interrupt LEQSELVI treatment until the infection is controlled .
Hematological Abnormalities
Recommendations for LEQSELVI treatment interruption for hematologic abnormalities are described in
Table 1
.
Laboratory Measure | Interruption Criterion | Resumption Criterion
Absolute Lymphocyte Count (ALC) | <500 cells/mm3 | ≥500 cells/mm3
Absolute Neutrophil Count (ANC) | <1000 cells/mm3 | ≥1000 cells/mm3
Hemoglobin | <8 g/dL | ≥8 g/dL
How to take Deuruxolitinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (
Medication Guide
)
Serious Infections
Advise patients that they are more likely to develop infections when taking LEQSELVI.
Advise patients that the risk of herpes zoster is increased in patients treated with LEQSELVI and some cases can be serious .
Instruct patients to tell their healthcare provider if they develop any signs or symptoms of an infection .
Malignancies and Lymphoproliferative Disorders
Inform patients that LEQSELVI may increase the risk of developing certain cancers, including skin cancers, and that periodic skin examinations should be performed while using LEQSELVI. Instruct patients to inform their healthcare provider if they have ever had any type of cancer .
Major Adverse Cardiovascular Events
Inform patients that LEQSELVI may increase the risk of major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular death. Instruct all patients, especially current or past smokers or patients with other cardiovascular risk factors, to be alert for the development of signs and symptoms of cardiovascular events . …
Warnings & precautions
Do not take this medicine if: LEQSELVI is contraindicated in patients who:
Are CYP2C9 poor metabolizers .
Are on concomitant moderate or strong CYP2C9 inhibitors .
Serious infections have been reported in subjects with alopecia areata receiving LEQSELVI .
Avoid use of LEQSELVI in patients with an active, serious infection including localized infections.
Prior to LEQSELVI treatment, consider the risks and benefits in patients:
with chronic or recurrent infection
who have been exposed to tuberculosis
with a history of a serious or opportunistic infection
who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or
with underlying conditions that may predispose them to infection
Closely monitor patients for the development of signs and symptoms of infection during and after treatment with LEQSELVI. If the patient develops a serious infection, interrupt treatment with LEQSELVI until the infection resolves or is adequately treated. If a patient develops a new infection during treatment with LEQSELVI, initiate complete diagnostic testing appropriate for an immunocompromised patient and appropriate antimicrobial therapy.
Tuberculosis
Evaluate patients for latent and active tuberculosis (TB) infection prior to LEQSELVI treatment. LEQSELVI is not recommended for use in patients with active TB.
Treat patients with latent TB before LEQSELVI treatment. Consider anti-TB therapy prior to LEQSELVI treatment in patients with previously untreated latent TB or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient. …
Deuruxolitinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Serious Infections
Malignancy and Lymphoproliferative Disorders
Thrombosis
Gastrointestinal perforations
Lipid Elevations, Anemia, Neutropenia and Lymphopenia
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of LEQSELVI was evaluated in three randomized, placebo-controlled clinical trials (including a dose-ranging trial), two open-label trials, and two long-term extension trials in adult subjects with severe alopecia areata. These subjects had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT) for more than six months. A total of 1,730 subjects with alopecia areata were treated across all trials, representing 1,962.9 patient-years of exposure. There were 974 subjects who were exposed to either LEQSELVI 8 mg or deuruxolitinib 12 mg for at least 1 year and 104 subjects who were exposed for at least 3 years.
Deuruxolitinib 12 mg is not approved.
Among 1,020 subjects enrolled in the placebo-controlled clinical trials, 640 subjects received LEQSELVI 8 mg twice daily, 380 subjects received deuruxolitinib 12 mg twice daily and 299 subjects received placebo twice daily for up to 24 weeks . …
Drug interactions
Effect of Other Drugs on LEQSELVI
Strong CYP3A and moderate or strong CYP2C9 inducers:
Avoid concomitant use of LEQSELVI with strong CYP3A and moderate or strong CYP2C9 inducers.
Deuruxolitinib is a CYP2C9 and CYP3A substrate. Concomitant use with a strong CYP3A and moderate or strong CYP2C9 inducer decreases deuruxolitinib exposure (Cmax and AUC), which may reduce LEQSELVI efficacy .
Moderate or strong CYP2C9 inhibitors:
LEQSELVI is contraindicated in patients taking moderate or strong CYP2C9 inhibitors .
Deuruxolitinib is a CYP2C9 substrate. Concomitant use with a moderate or strong CYP2C9 inhibitor is estimated to increase deuruxolitinib exposure (Cmax and AUC), which may increase the risk of LEQSELVI serious adverse reactions such as thrombosis .
About this medicine
LEQSELVI (deuruxolitinib) tablets contain the phosphate salt of deuruxolitinib, a Janus kinase (JAK) inhibitor, for oral administration.
Deuruxolitinib phosphate is a white to off-white crystalline solid with the chemical name 1H-Pyrazole-1-propanenitrile, β-(cyclopentyl-2,2,3,3,4,4,5,5-d
8)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)-, phosphate (1:1).
Deuruxolitinib has high aqueous solubility at low pH. Deuruxolitinib phosphate has a molecular weight of 412.42 g/mol and a molecular formula of C17H13D8N6O4P. The structural formula is:
Each tablet contains 8 mg of deuruxolitinib (equivalent to 10.50 mg of deuruxolitinib phosphate) and the following excipients: colloidal silicon dioxide, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose and povidone. The tablet film coating contains the following excipients: carmine, FD&C blue #2 aluminum lake, glyceryl mono and dicaprylocaprate, polyvinyl alcohol, sodium lauryl sulfate, talc, and titanium dioxide.
How it works: Deuruxolitinib is a Janus kinase (JAK) inhibitor. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a603f231-d09e-4bad-ad5e-b55f865da095. Read the full official label on DailyMed.